So, there is this thing called Porch Group that helps people with home stuff and they have some important people who work for them. Some of these important people bought more shares of the company because they think it's a good idea to own more of it. This might mean they believe the company will do well in the future. Read from source...

- The article title is misleading and clickbaity. It suggests that insiders are buying three stocks under $3, but only one of them (Porch Group) has an actual insider transaction mentioned in the text. BioRestorative Therapies and Porch Group have different directors acquiring shares, which may or may not indicate confidence or concern about the company's prospects.
- The article does not provide any context or analysis of why these stocks are under $3 or what factors could affect their price movements. It also does not mention the market capitalization, revenue, earnings, or growth potential of these companies. This makes it difficult for readers to evaluate the value and risks of investing in them.
- The article focuses on a single recent event (the insider transaction) without considering the broader trends or performance of these stocks over time. It also does not compare them to other similar or competitive stocks in the same sector or industry. This limits the perspective and usefulness of the information for readers who want to make informed decisions based on multiple factors and sources.

Bullish

Explanation: The article is about insiders buying stocks under $3, which indicates their confidence in the company's prospects. This can be seen as a positive sign for investors and traders interested in penny stocks. Additionally, Porch Group has signed a strategic business collaboration agreement, which could also boost the company's outlook.

1. Porch Group (PRCH): Buy with a target price of $5. This stock has strong growth potential as the company is expanding its services in the home improvement and professional services market. The insider purchase by Camilla Velasquez, a director, indicates confidence in the company's future prospects. However, there are risks involved due to the volatile nature of the penny stock market and the uncertainty around the company's profitability.
2. BioRestorative Therapies (BRTX): Sell with a stop loss at $2. This stock is highly speculative and has no revenues or significant clinical trials to support its therapeutic products. The insider selling by the CEO, Lance Alstodt, suggests that he may be aware of some negative news or developments that could hurt the stock price. There are also risks related to the regulatory approval process and the competition in the regenerative medicine sector.
3. BioRestorative Therapies (BRTX): Sell with a stop loss at $2. This stock is highly speculative and has no revenues or significant clinical trials to support its therapeutic products. The insider selling by the CEO, Lance Alstodt, suggests that he may be aware of some negative news or developments that could hurt the stock price. There are also risks related to the regulatory approval process and the competition in the regenerative medicine sector.